Corticotropin-releasing factor decreases vasogenic brain edema

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1352-1360

  Tjuvajev, Juri ^a   Uehara, Hisao ^a   Desai, Revathi ^a   Beattie, Bradley ^a   Matei, Cornelia ^a   Zhou, Yan ^b   Kreek, Mary Jeanne ^b   Koutcher, Jason ^a   Blasberg, Ronald ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; GLIOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SURVIVAL TIME; TISSUE WATER; WATER CONTENT;

ADRENALECTOMY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS; BLOOD-BRAIN BARRIER; BODY WATER; BRAIN EDEMA; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GLIOMA; MAGNETIC RESONANCE IMAGING; RATS; RATS, INBRED F344;

EID: 0029939878     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Galicich, J. H., French, L A., and Melby, J. C. Use of dexamethasone in the treatment of cerebral edema associated with brain tumors. Lancet, 81: 46-53, 1961
2. Greenberg, H. S , Kim, J. H , and Posner, J. B. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann. Neurol., 8: 361-366, 1980.
3. Marshall, L. F., King, J , and Langfitt, T. W. The complications of high-dose corticosteroid therapy in neurosurgical patients: a prospective study. Ann. Neurol., 1 201-203, 1977
4. Martenson, J. A. J , Evans, R G., Lie, M R., Ilstrup, D M , Dinapoli, R. P., Ebersold, M. J , and Earle, J. D Treatment outcome and complications in patients treated for malignant epidural spinal cord compression. J. Neuro-Oncol., 3: 77-84, 1985.
5. Pezner, R D , and Lipsett, J A. Peptic ulcer disease and other complications in patients receiving dexamethasone palliation for brain metastasis West. J. Med., 137 375-378, 1982.
6. Slatkin, N. E., and Posner, J B. Management of spinal epidural metastases. Clin. Neurosurg., 30: 698-716, 1983.
7. Warshaw, A L , Welch J P., and Ottinger, L. W. Acute perforation of the colon associated with chronic corticosteroid therapv Am. J. Surg., 131: 442-146, 1976.
8. Weissman, D. E., Dufer, D. Vogel, V., and Abeloff, M D. Corticosteroid toxicity in neuro-oncology patients. J Neuro-Oncol , 5: 125-128, 1987.
9. Kiang, J. G., Poree, L., and Wei, E. T Anti-inflammatory activity of corticotropin-releasing factor. II. Mechanisms of action. Proc West. Pharmacol. Soc., 30: 63-65, 1987
10. Serda, S. M., and Wei, E. T. Epinephrine-induced pulmonary edema in rats is inhibited by corticotropin-releasing factor Pharmacol Res , 26: 85-91, 1992.
11. Wei, E T., and Thomas, H. A. Anti-inflammatory peptide agonists In A Cho, T S. Blaschle, H. H Loh, and J. L Wei (eds.), Annual Review of Pharmacology and Toxicology, Vol. 33, pp 258-268 Palo Alto Annual Reviews, 1993.
12. Wei, E. T., Gao, G. C., and Sessler, D. I. CRF inhibits the flare response to intradermal histamine in man. Clin. Pharmacol. Therapeut., 47: 192, 1990.
13. Wei, E. T., and Gao, G. C. Corticotropin-releasing factor an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury Regul Pept , 33: 93-104, 1991
14. Wei, E T., Gao, G. C , and Thomas, H A Peripheral anti-inflammatory actions of CRF In: D. J. Chadwick, J. Marsh, and K. Ackrill (eds.), Ciba Foundation Symposium No. 172 on Corticotropin Releasing Factor, pp 258-268 New York: John Wiley & Sons, Inc , 1993
15. Vale, W., Spiess, J , and Rivier, J. Characterisation of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin Science (Washington DC), 213 1392-1397, 1981
16. Dunn, A. J., and Berridge, C W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Bull , 15: 71-100, 1990
17. Joseph, S A., Pilcher, W H., and Knigge, K. M Anatomy of the corticotropin-releasing factor and opiomelaninocortin systems of the brain Fed Proc , 44 100-107, 1985.
18. Weiss, S R., Post, R. M , Gold, P W , Chrousos, G , Sullivan, T. L , Walker, D , and Pert, A. CRF-induced seizures and behavior, interaction with amygdala kindling Brain Res , 372: 345-351, 1986
19. Koob, G F , Heinrichs, S C , Pich, E M , Menzaghi, F., Baldwin, H., Miczek, K., and Britton, K. T The role of corticotropin-releasing factor in behavioral responses, to stress. Ciba Found. Symp , 172: 277-295, 1993.
20. Tjuvajev, J , Gansbacher, B., Desai, R , Beattie, B., Kaplitt, M , Matei, C., Koutcher, J. Gilboa, E., and Blasberg, R. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res., 55: 1902-1910, 1995.
21. Groothuis, D. R , Pasternak, J. F., Fischer, J M., Blasberg, R. G , Bigner, D. D., and Vick, N A. Measurement of regional blood flow in RG-2 experimental brain tumors. Cancer Res., 43: 3362-3367, 1983.
22. Groothuis, D. R., Fischer, J. M., Pasternak, J. F., Blasberg, R. G , Bigner, D D , and Vick, N. A. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas Cancer Res., 43: 3368-3373, 1983
23. 125I]albumin and adjacent brain J. Cereb Blood Flow Metab., 7: 687-701, 1987.
24. Nakagawa, H , Groothuis, D. R., Owens, E. S , Patlak, C. S., Pettigrew, K., and Blasberg, R. G. Dexamethasone effects on vascular volume and tissue hematocrit in experimental RG-2 gliomas and adjacent brain. J. Neuro-Oncol , 6: 157-168, 1988.
25. Moldow, R., and Fischman, A. Circadian rhythm of corticotropin releasing factor-like immunoreactivity in rat hypothalamus Peptides, 5: 1213-1215, 1984.
26. Chao, H. M., and McEwen, B S Glucocorticoid regulation of neuropeptide mRNAs in the rat striatum Mol. Brain Res., 9: 307-311, 1991
27. Axelrod, L Glucocorticoid therapy. Medicine (Baltimore), 55: 39-65, 1976.
28. Oikarinen, A I., Uitto, J., and Oikarinen, J Glucocorticoid action on connective tissue: from molecular mechanisms to clinical practice. Med Biol. (Helskinki), 64 221-230, 1986.
29. Askari, A., Vignos, P. J , and Moskowitz, R W. Steroid myopathy in connective tissue disease. Am. J. Med., 61: 485-492, 1976.
30. Bowyer, S. L., LaMonte, M. P , and Hollister, J. R Steroid myopathy: incidence and detection in a population with asthma J. Allergy Clin. Med., 76 234-242, 1985.
31. Horber, F F , Scheidegger, J. R , Grunig, B E , and Frey, F J Thigh muscle mass and function in patients treated with glucocorticoids Eur J. Clin. Invest. 15: 302-307, 1985
32. Taylor, L P , and Posner, J B Steroid myopathy in cancer patients treated with dexamethasone. Neurology, 39 (Suppl. 1) 129, 1989.
33. Lukert, B. P , and Raiz, L. G. Glucocorticoid-induced osteoporosis pathogenesis and management. Ann Intern Med , 22: 352-364, 1990.
34. Engel, I. A., Straus, D. J , Lacher, M., Lane, J , and Smith, J Osteonecrosis in patients with malignant lymphoma, a review of 25 cases Cancer (Phila.), 48: 1245-1250, 1981
35. Fast, A., Alon, M., Weiss, S , and Zer-Aviv, F R Avascular necrosis of bone following short-term dexamethasone therapy for brain edema J Neurosurg , 61 983-985, 1984
36. Naul, L G., Peet, G. J , and Maupin, W. B Avascular necrosis of the vertebral body MR imaging. Radiology, 772: 219-222, 1989
37. Messer, J , Reitman, D., Saks, H S., Smith, H , Jr , and Chalmers, T. C Association of adrenocorticosteroid therapy and peptic-ulcer disease N. Engl. J Med., 309: 21-24, 1983
38. Sauer, E. G , Dearing, W. H., and Wollaeger, E E. Serious untoward gastrointestinal manifestations possibly related to administration of cortisone and corticotropin. Proc Staff Meet Mayo Clin., 28: 641-649, 1953.
39. Breibart, W , Steifel, F , and Kornblith, A B. Neuropsychiatric disturbance in cancer patients with epidural spinal cord compression receiving high dose corticosteroids a prospective comparison study. Psycho-oncology, 2: 233-245, 1993
40. Wolkowitz, O M , Reus, V. I , Weingartner, H , Thompson, K , Breier, A , Doran, A , Rubinow, D , and Pickar, D Cognitive effects of corticosteroids. Am. J Psychiatry, 147: 1297-1303, 1990
41. Lewis, D. A., and Smith, R. E Steroid-induced psychiatric syndrome a report of 14 cases and review of the literature J Affective Disord , 5 319-322, 1983
42. Steifel, F C , Breibart, W S , and Holland, J. C. Corticosteroids in cancer neuropsychiatric complications. Cancer Invest , 7: 479-491, 1989
43. David-Nelson, M., and Brodish, A. Evidence for a diurnal rhythm of corticotropin-releasing factor (CRF) in the hypothalamus. Endocrinology, 85: 861-866, 1969.
44. Rivier, C., and Vale, W. Influence of the frequency of ovine corticotropin-releasing factor administration on adrenocorticotropin and corticosterone secretion in the rat. Endocrinology, 113: 1422-1426, 1983.
45. Rivier, C., and Vale, W. Effect of long-term administration of corticotropin-releasing factor on the pituitary-adrenal and pituitary-gonadal axis in male rat. J. Clin Invest , 75: 689-694, 1985.
46. Schulte, H. M., Chrousos, G. R. Gold, P W , Booth, E. H., Oldfield, E H , Cutler, G B , and Loriaux, D L. Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications. J Clin Invest., 75: 1781-1785, 1985.
47. Eberwine, J. H., Jonassen, J. A., Evinger, M. J. Q., and Roberts, J. Complex transcriptional regulation by glucocorticoids and corticotropin-releasing hormone of proopiomelaninocortin gene expression in rat pituitary cultures. DNA, 6: 483-492, 1987
48. 2+ channels in human epidermoid A-431 cells Eur. J Pharmacol , 267: 135-142, 1994.
49. Chang, C-P., Pearse, R. V., O'Connel, S , and Rosenfeld, M. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. 11: 1187-1195, 1993
50. Potter, E , Sutton, S., Donaldson, C., Chen, R., Perrin, M , Lewis, K., Sawchenko, P E , and Vale, W Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary Proc. Natl. Acad. Sci. USA, 91: 8777-8781, 1994.
51. Lovenberg, T. W., Liaw, C. W , Grigoriadis, D. E., Clevenger, W., Chalmers, D. T., De Souza, E. B., and Oltersdorf, T Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA, 92: 836-840, 1995.
52. Kishimoto, T., Pearse, R. V., Lin, R C., and Rosenfeld, M. G. A sauvagine/ corticotropin-releasing factor receptor expressed in heart and skeletal muscle Proc Natl. Acad. Sci. USA, 92: 1108-1112, 1995.
53. Luini, A , Lewis, D , Guild, S., Corda, D , and Axelrod, J. Hormone secretogogues elevate cytosolic calcium by increasing cAMP in corticotropin secreting cells. Proc Natl. Acad. Sci. USA, 82: 3034-3038, 1985.
54. Rivier, J., Rivier, C., and Vale, W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science (Washington DC), 224: 889-891, 1984.
55. 125I]-Tyr-corticoliberin-releasing factor to rabbit aorta is reduced by removal of endothelium. Eur J Pharmacol., 135: 111-112, 1987
56. Wei, E. T , and Kiang, J G. Peptides of the corticoliberin superfamily inhibit thermal and neurogenic inflammation. Eur. J. Pharmacol., 168: 81-86, 1989.
57. Kiang, J. G , and Wei, E. T. CRF-evoked bradycardia in urethane-anesthetized rats is blocked by naloxone. Peptides, 6: 409-413, 1984.
58. Hermus, A , Pieters, G., Willemsen, J., Ross, H A., Smals, A. G., Benraad, T J., and Kloppenborg, P. W. Hypotensive effects of ovine and human corticotropin-releasing factor. Eur J. Clin. Pharmacol., 31: 531-534, 1987.
59. Sternberger, N. H., Sternberger, L A., Kies, M. W., and Shear, C. R. Cell surface endothelial proteins altered in experimental allergic encephalomyelitis. J. Neuroimmunol., 21 241-248, 1989.
60. Sternberger, N. H., and Sternberger, L A. Blood-brain barrier protein recognized by monoclonal antibody. Proc. Natl. Acad. Sci USA, 84: 8169-8173, 1987.
61. Westendorp, R. G., Draijer, R., Meinders, A. E , and van Hinsbergh, V. W. Cyclic-GMP-mediated decrease in permeability of human umbilical and pulmonary artery endothelial cell monolayers J Vasc. Res., 31: 42-51, 1994.
62. Janigro, D., West, G. A., Nguyen, T. S., and Winn, H. R. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ. Res., 75: 528-538, 1994
63. Thomas, H. A., Ling, N., Wei, E. T., Berree, F , Cobas, A., and Rapoport, H. J. Novel anti-inflammatory undecapeptides that contain anisolylated glutamic acid derivatives J. Pharmacol. Exp. Ther., 267: 1321-1326, 1993.
64. Hanukoglu, L. and Fuchs, E. The cDNA sequence of a type II cytoskeletal keratin reveals constant and variable structural domains among keratins. Cell, 33: 915-924, 1983.
65. Quax, W., Egberts, W V., Hendriks, W., Quax-Jeuken, Y , and Bloemendal, H. The structure of the vimentin gene. Cell, 35: 215-223, 1983.
66. Nagle, R. B Intermediate filaments: a review of basic biology. Am. J. Surg Pathol., 1 (Suppl. 12): 4-16, 1988.
67. Alexander, J S , Patton, W. F., Yoon, M. Y , and Shepro, D. Cytokeratin filament modulation in pulmonary microvascular endothelial cells by vasoactive agents and culture confluency. Tissue Cell, 23: 141-150, 1991.
68. Goldman, G , Welbourn, R., Alexander, S., Klausner, J. M., and Wiles, M. Modulation of pulmonory permeability in vivo with agents that effect the cytoskeleton Surgery, 109: 533-538, 1991.
69. Letai, A. Coulombe, P. A., and Fuchs, E. Do the ends justify the means? Proline mutations at the ends of the keratin coiled-coil rod segment are more disruptive than internal mutations. J Cell Biol., 116 1181-1195, 1992.
70. Jarden, J. O., Dhawan, V., Poltorak, A., Posner, J. B., and Rottenberg, D A. Positron emission tomographic measurement of blood-to-tumor transport of 82Rb, the effect of dexamethasone and whole brain radiation therapy Ann. Neurol., 18: 643-646, 1985
71. Molnar, P., Lapin, G. D., and Groothuis, D. R. The effects of dexamethasone on experimental brain tumors. I. Transcapillary transport and blood flow in RG-2 rat gliomas. J. Neuro-Oncol., 25: 19-28, 1995.
72. Warnke, P C., Molnar, P., Lapin, G. D., Kuruvilla, A., and Groothuis, D. R The effects of dexamethasone on transcapillary transport in experimental brain tumors. II Canine brain tumors. J Neuro-Oncol , 25: 29-38, 1995.
73. Drayer, J. M., Weber, M A , Purdy, R. E., and Lipson, J. L. The effects of steroid hormones on vascular tissue. J. Cardiovasc. Pharmacol., 6: 394-400, 1984.
74. Kelly, F. J., McGrath, S. A , Goldspink, D. F., and Cullen, M. J. A morphological/ biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle & Nerve, 9: 1-10, 1986.
75. Seene, T., Umnova, M., Alev, K., and Pehme, A. Effect of glucocorticoids on contractile apparatus of rat skeletal muscle. J. Steroid Biochem., 29: 313-317, 1988.
76. Horak, V., and Matolin, S. Inhibition reactivation myofibrillar ATPase technique for demonstration of three fiber types in a single cryostat muscle section. Stain Technol , 65: 85-89, 1990